Modified PEI/PLGA Nanoparticles Improve Pharmacokinetics of Chikusetsusaponin IVa for Sustained Drug Delivery

A recent study has explored the enhancement of pharmacokinetic properties of Chikusetsusaponin IVa through the use of modified nanoparticles. Researchers investigated how polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles could be engineered to enable sustained drug delivery, potentially improving the compound’s therapeutic efficacy and bioavailability.

The study focused on modifying PEI/PLGA nanoparticles to optimize their ability to deliver Chikusetsusaponin IVa over an extended period. Researchers analyzed the structural and functional changes in these nanoparticles, assessing their impact on drug release rates, stability, and absorption in biological systems. The findings indicated that the modified nanoparticle system demonstrated improved pharmacokinetic profiles compared to traditional delivery methods. This approach may provide a foundation for further research into nanoparticle-based drug delivery systems aimed at enhancing the effectiveness of bioactive compounds.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

New strategy may enable cancer monitoring from blood tests alone Generative AI System Boosts Radiologist Productivity by 40 Percent at Northwestern Medicine Roche Positions Zilebesiran as Best-in-Disease Anti-Hypertensive Amid AstraZeneca’s Phase III Success with Baxdrostat Microbial CMOs Gain Market Share as Innovators Outsource Biologics Production

Author

GOAI